IN8BIO, INC. Segments Disclosure
14. SEGMENTS
Operating segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation by the CODM or decision-making group in making decisions on how to allocate resources and assess performance. The Company has one operating segment focused on the discovery, development and commercialization of gamma-delta T cell product candidates for solid and liquid tumors. The CODM is the Company’s CEO. The CEO manages the Company’s operations on a consolidated basis, assesses performance for the operating segment and decides how to allocate resources based on consolidated net loss, which is reported on the consolidated statements of operations. Depreciation expense, amortization expense, stock-based compensation expense, and non-cash lease expense are significant noncash items included in consolidated net loss reviewed by the CEO and are reported on the consolidated statements of cash flows. The measure of segment assets is reported on the consolidated balance sheets as total consolidated assets.
The following table presents certain financial data for the Company’s reportable segment:
|
|
Year Ended |
|
|||||
|
|
2025 |
|
|
2024 |
|
||
INB-100 research and development expenses |
|
$ |
974 |
|
|
$ |
913 |
|
INB-200 research and development expenses |
|
|
15 |
|
|
|
451 |
|
INB-400 research and development expenses |
|
|
697 |
|
|
|
4,677 |
|
Personnel-related indirect research and development expenses |
|
|
5,294 |
|
|
|
7,674 |
|
Total general and administrative expenses |
|
|
9,650 |
|
|
|
12,637 |
|
Other segment items1 |
|
|
2,810 |
|
|
|
4,085 |
|
Segment net loss |
|
$ |
19,440 |
|
|
$ |
30,437 |
|
(1) Other segment items include preclinical expenses, severance and related charges, and interest income.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 12, 2026 | Showing above |
| 2024 | Mar 13, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.